Hermes Vector

Health

American Cancer Society Updates Prostate Cancer Screening Guidelines

The American Cancer Society has updated its prostate cancer screening guidelines for the first time since 2010, recommending biennial PSA testing for average-risk men ages 50-69 and annual screening for higher-risk groups starting at age 45.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · हिन्दी · 中文

Checked against 6 sourceswfmz.comrenalandurologynews.comoncodaily.comuofmhealth.orgmichiganmedicine.orgthehypemagazine.com
Illustration for: American Cancer Society Updates Prostate Cancer Screening Guidelines

In brief

  • ACS updates prostate cancer screening guidelines for the first time since 2010
  • Average-risk men ages 50-69 should get PSA screening every two years
  • Black men and men with strong family history should get annual screening starting at age 45
  • No routine screening recommended for men aged 75 and older

American Cancer Society Updates Prostate Cancer Screening Guidelines

The American Cancer Society has updated its prostate cancer screening guidelines for the first time since 2010, according to multiple news reports. The full guideline update was published in CA: A Cancer Journal for Clinicians.

Screening recommendations by risk group

The updated guidelines recommend:

  • PSA-based screening every two years for men aged 50-69 at average risk for prostate cancer
  • Yearly PSA-based screening for Black men ages 45-69
  • Yearly PSA-based screening for men with a strong family history of prostate cancer starting at age 45
  • Screening every two years from ages 45-69 for non-Black men with a single first-degree relative diagnosed at age 65 or older
  • Individualized decision-making for men aged 70-74 in consultation with a health care provider
  • No routine screening for men aged 75 and older

Follow-up and next steps

If the initial PSA level is 3.0 ng/mL or higher in a man aged 45-69 years, or 6.5 ng/mL or higher in a man aged 70 to 74 years, clinicians should wait two weeks then order repeat PSA testing within three months to confirm a rise. If elevated PSA is confirmed, clinicians should order prostate magnetic resonance imaging (MRI) and/or a validated biomarker test to guide the decision to biopsy.

Active surveillance is the preferred initial management option for low-risk prostate cancer. The guidelines also note that PSA testing may catch disease before it is advanced and reduce the risk of early death, while potential harms include overtreatment and bleeding, pain, fever, and/or possible infection from prostate biopsy.

Expert commentary

"PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits," stated Robert Smith, MD, senior vice president, early cancer detection science, and director, Center for Early Cancer Detection at the American Cancer Society and senior author of the report. "We also have better approaches to catching lethal tumors while avoiding unnecessary tests for slow-growing cancers that may never need aggressive care."

Dr. Ed Trabulsi, a urologist with Jefferson Health, told 69 News that screenings typically involve a prostate-specific antigen, or PSA blood test. "It's a very important update that strengthens the guidelines to utilize the PSA blood test to really try to catch prostate cancer early," Trabulsi stated.

Simpa Salami, M.D., M.P.H., of the University of Michigan Rogel Cancer Center, said: "The updated ACS guidelines are an important step forward — they signal that we can no longer afford a one size fits all approach to prostate cancer screening."

Why it matters

Prostate cancer is the most common cancer in American men and the second most common cause of death in men, with 1 in 8 men diagnosed in their lifetime, according to WFMZ. The update reflects stronger evidence of the benefits of PSA-based screening and the emergence of management strategies that can reduce harms, based on a systematic review involving 29 publications and multiple clinical trials.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

When were the American Cancer Society's prostate cancer screening guidelines last updated before this release?
The guidelines were last updated in 2010.
What are the new screening recommendations for men aged 50-69 at average risk?
Men aged 50-69 at average risk should undergo PSA-based screening every two years.
Who is recommended to have yearly PSA-based screening starting at age 45?
Black men and men with a strong family history of prostate cancer are recommended to have yearly screening starting at age 45.
Why does the American Cancer Society consider this update important?
The update reflects stronger evidence of the benefits of PSA-based screening and the emergence of management strategies that can reduce harms.
What is the preferred initial management option for low-risk prostate cancer?
Active surveillance is the preferred initial management option for low-risk prostate cancer.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.